Arrowhead Pharmaceuticals vs Liquidia
ARWR and LQDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARWR and LQDA compare
Arrowhead Pharmaceuticals is the larger company, worth 1.2 times as much as Liquidia ($6.1B against $5.1B).
Liquidia grew revenue faster over the last twelve months (2234% versus 16.8% for Arrowhead Pharmaceuticals).
Liquidia keeps more of each dollar of sales as profit, with a net margin of 30.7% compared with −47.8% at Arrowhead Pharmaceuticals.
Liquidia scores higher on the StockData Score (8 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARWR | LQDA |
|---|---|---|
| Size and price | ||
| Market cap | $6.1B | $5.1B |
| Share price | $42.99 | $56.73 |
| Change, 1 year | 4.2% | 102% |
| Change, 5 years | −40.3% | 1280% |
| Beta (5Y) | 1.57 | 1.00 |
| Employees | 711 | 216 |
| StockData Score | ||
| Total score | 5 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 40.8× |
| P/S | 9.1× (better) | 11.3× |
| P/B | 13.0× (better) | 26.0× |
| EV/EBITDA | – | 28.2× |
| P/FCF | – | 33.7× |
| FCF yield | −1.2% | 3.0% (better) |
| Fair value | $31.89 | $32.46 |
| Margin of safety | −34.8% (better) | −74.8% |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 2234% (better) |
| Revenue growth, 5Y average | 56.6% | 192% (better) |
| Profitability | ||
| Operating margin | −33.8% | 37.4% (better) |
| Net margin | −47.8% | 30.7% (better) |
| FCF margin | −11.2% | 33.4% (better) |
| Return on equity | −64.8% | 132% (better) |
| Financial health | ||
| Interest coverage | −2.4× | 6.3× (better) |
| Current ratio | 5.90 (better) | 2.31 |
| Altman Z-score | 1.69 | 10.49 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.6% | 81.1% |
| Held by insiders | 4.0% | 19.5% |
| Insider net buying, 12 months | −$36.9M (better) | −$227M |
| Short interest, % of float | 8.5% | 24.3% |
Go deeper
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
- LQDA stock overview
- LQDA income statement
- LQDA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.